Patient and Nurse Satisfaction with the New Lanreotide Autogel Pre-Filled Syringe in Neuroendocrine Tumors (NET): A Prospective Study (SONATE)

#2824

Introduction: A new syringe (NS) for the delivery of lanreotide autogel was approved in Oct 2018 in France. The NS includes updated features (larger flanges, more robust plunger) intended to ease the injection.

Aim(s): To prospectively assess satisfaction with the NS vs the former syringe (FS) in patients (pts) with NET and nurses.

Materials and methods: Dedicated questionnaires (assessing pain, anxiety and satisfaction) were administered over the telephone by a pharmacist and a nurse in Mar-Apr 2019 (for FS), then in Sep-Oct. 2019 (after 3 mths’ NS use). Pts from 2 French referral centers and their treating nurses were contacted on separate calls. Descriptive statistics, Fisher, Pearson tests were used.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Walter T, Eskenazi M, Rama N, Gueguen D, Mir O,

Keywords: neuroendocrine tumors, lanreotide, nursing, patient-reported outcomes,